Aastrom Biosciences, Inc. Announces Strategic Plan For Recently Acquired Cell Therapy And Regenerative Medicine Business
Published: Jun 16, 2014
ANN ARBOR, Mich., June 16, 2014 (GLOBE NEWSWIRE) -- Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of patient-specific expanded cellular therapies for the treatment of severe diseases and conditions, today announced its strategic plan to maximize the profitability and growth potential of the cell therapy and regenerative medicine business that it recently acquired from Sanofi.
Help employers find you! Check out all the jobs and post your resume.